The trial reached equally its Most important endpoints, with semaglutide two.4 mg demonstrating statistically major and outstanding enhancements in liver fibrosis with no worsening of steatohepatitis, and also resolution of steatohepatitis with no worsening of liver fibrosis in people with MASH in c